企業プロフィール
ABVC BioPharma, Inc. 株価・ニュース・カタリスト
- ティッカー:
- ABVC
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States and trades on NASDAQ, placing it in the small-cap biotech category
株価パフォーマンス
1.02 USD (-3.77%)
終値
最終更新: 2026年10月1日
32.5M USD
時価総額
株価変動の要因
2026年10月1日 時点で ABVC は 3.77% 下落し、$1.02 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Botanical Drug and Medical Device Developer
ABVC BioPharma develops drug candidates and medical devices originating from botanical compounds and academic research. The portfolio spans central nervous system disorders, oncology, ophthalmology, and women's health.
ABV-1505 for Adult ADHD
ABV-1505 is a botanical drug candidate being studied for adult attention-deficit hyperactivity disorder. The program is intended to offer a non-stimulant treatment approach through a standardized extract and regulated clinical-development pathway.
Vitargus Vitreous Substitute
Vitargus is a bioengineered hydrogel being developed as a vitreous substitute for retinal surgery. The material is designed to maintain the space and optical properties of the eye after removal of the natural vitreous.
Oncology and Additional Programs
The pipeline includes ABV-1519 for non-small cell lung cancer and other botanical candidates licensed from research institutions. Development is conducted through subsidiaries, academic collaborations, and regional clinical partners.
BioFirst Structure
ABVC has organized several development assets through BioFirst and related entities. This structure can support separate financing, partnering, or strategic transactions around individual programs.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。